Insider Sale: Head of Fin. Quality Assurance at IRD sold 3,950 Shares

Zaremba Rabourn Amy, a Head of Fin. Quality Assurance at Opus Genetics (NASDAQ: IRD), sold 3,950 shares of the company on Jan 10, 2026, for an estimated 7,624. This was a sale of approximately 3.5% of their shares of this class of stock. After the trade, they now own 110,018 shares of this class of IRD stock.

Opus Genetics Insider Trading Activity

Opus Genetics insiders have traded IRD stock on the open market 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 has been a sale.

Here’s a breakdown of recent trading of IRD stock by insiders over the last 6 months:

• Opus Genetics, Inc. [IRD] (director by deputization of Issuer) sold 4,000,000 shares for an estimated 8,600,000.
• Gallagher Cam has made 2 purchases, buying 164,000 shares for an estimated 323,693 and 0 sales.

Opus Genetics Hedge Fund Activity

We have seen 1 institutional investor add shares of IRD stock to their portfolio, while 6 reduced their positions in their most recent quarter.

Here are some of the largest recent moves:

• Northern Trust Corporation removed 3,957,095 shares of IRD, for an estimated 7,045,658
• Bank Of America Corporation removed 3,931,455 shares of IRD, for an estimated 7,003,393
• The Vanguard Group, Inc. removed 183,544 shares of IRD, for an estimated 302,848
• Blackrock, Inc. added 43,588 shares of IRD, for an estimated 71,921
• Royal Bank Of Canada removed 42,106 shares of IRD, for an estimated 69,442
• Ubs Group Ag removed 116 shares of IRD, for an estimated 191
• Xtx Topco Ltd removed 5 shares of IRD, for an estimated 0

Opus Genetics Revenue

Opus Genetics had revenues of 3.1M in Q3 2025. That marks a 20.38% drop from the same period last year.